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a b s t r a c t
Epalrestat (EPS), approved in Japan, is the only aldose reductase inhibitor that is currently available for
the treatment of diabetic neuropathy. Here we report that EPS at near-plasma concentration increases
the intracellular levels of glutathione (GSH), which is important for protection against oxidative injury,
through transcription regulation. Treatment of Schwann cells with EPS caused a dramatic increase in
intracellular GSH levels. EPS increased the mRNA levels of γ-glutamylcysteine synthetase (γ-GCS), the
enzyme catalyzing the ﬁrst and rate-limiting step in de novo GSH synthesis. Nuclear factor erythroid 2-
related factor 2 (Nrf2) is a key transcription factor that plays a central role in regulating the expression of
γ-GCS. ELISA revealed that EPS increased nuclear Nrf2 levels. Knockdown of Nrf2 by siRNA suppressed
the EPS-induced GSH biosynthesis. Furthermore, pretreatment with EPS reduced the cytotoxicity
induced by H2O2, tert-butylhydroperoxide, 2,2'-azobis (2-amidinopropane) dihydrochloride, and mena-
dione, indicating that EPS plays a role in protecting against oxidative stress. This is the ﬁrst study to show
that EPS induces GSH biosynthesis via the activation of Nrf2. We suggest that EPS has new beneﬁcial
properties that may prevent the development and progression of disorders caused by oxidative stress.
& 2013 The Authors. Published by Elsevier B.V. All rights reserved.
Introduction
Epalrestat (5-[(1Z,2E)-2-methyl-3-phenyl propenylidene]-4-
oxo-2-thioxo-3-thiazolidine acetic acid; EPS2), a carboxylic acid
derivative (Fig. 1), is an inhibitor of aldose reductase, a rate-
limiting enzyme in the polyol pathway. Under hyperglycemic
conditions, EPS reduces intracellular sorbitol accumulation, which
is implicated in the pathogenesis of diabetic complications [1].
Diabetic neuropathy is one of the most common long-term
complications in patients with diabetes mellitus. EPS is approved
in Japan for the alleviation of subjective neuropathy symptoms,
abnormality of vibration sense, and abnormal changes in heartbeat
associated with diabetic peripheral neuropathy. Data from experi-
mental studies indicate that EPS reduces sorbitol accumulation in
the sciatic nerve, erythrocytes, and ocular tissues in animals, and
in erythrocytes in humans. An evaluation of data from six clinical
trials showed that 50 mg of EPS administered three times a day
might improve motor and sensory nerve conduction velocity and
subjective neuropathy symptoms as compared with baseline and
placebo [2]. However, the basic effects of EPS on cells and tissues,
other than aldose reductase inhibition, have not been reported
so far.
Cell stress can greatly increase reactive oxygen species (ROS)
levels [3]. Because of their highly reactive nature, ROS can modify
other oxygen species, proteins, or lipids, a situation often termed
oxidative stress. In this regard, maintaining normal cellular ROS
levels is vital to the proper physiologic function of numerous cell
types in the body. The excessive production or the decreased
scavenging of ROS has been implicated in the pathogenesis of such
diseases as neurodegeneration [4,5], diabetes [6], and athero-
sclerosis [7,8]. Reduced glutathione (GSH), the most abundant
non-protein thiol antioxidant in cells, is important for protection
against oxidative injury [9]. γ-Glutamylcysteine synthetase
(γ-GCS) is the enzyme catalyzing the ﬁrst and rate-limiting step
in the de novo GSH synthesis [10]. Thus, the regulation of γ-GCS
expression and activity is critical for GSH homeostasis. Nuclear
factor erythroid 2-related factor 2 (Nrf2) is a key transcription
factor that plays a central role in regulating the expression of
antioxidant genes, including γ-GCS [11–13]. Nrf2 is retained in the
cytoplasm as an inactive complex with its cytosolic repressor,
Kelch-like ECH associated protein-1 (Keap1). The dissociation of
Nrf2 from Keap1 is crucial for its nuclear translocation, followed by
binding to DNA and activation of cytoprotective genes. Therefore,
Nrf2 is important for the maintenance of intracellular GSH levels
and redox homeostasis.
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In this study, we examined the effect of EPS on GSH biosynth-
esis in rat Schwann cells (SCs). We found that EPS increases GSH
levels through transcription regulation and induces the nuclear
translocation of Nrf2.
Materials and methods
Schwann cell culture and treatment with EPS
Rat SCs were purchased from Dainippon Sumitomo Pharma Co.,
Ltd. (Osaka, Japan). Cells were grown to 80–90% conﬂuence in
DMEM containing 10% fetal bovine serum (FBS), L-glutamine
(4 mM), penicillin (100 U/ml), and streptomycin (100 μg/ml) at
37 1C in a humidiﬁed atmosphere of 5% CO2 and 95% air. Then, the
cells were passaged by trypsinization.
Before treating the cells with EPS (Wako Pure Chemical
Industries, Ltd., Osaka, Japan), the culture medium was replaced
with DMEM containing 2% FBS because serum may include
antioxidants, chelates of transition metal ions, and high-density
lipoproteins [14]. EPS (10–200 μM) was subsequently added to the
medium.
Cell viability
Cell viability was assessed by using CellTiter 96s AQueous One
Solution Cell Proliferation Assay (MTS assay) from Promega
(Madison, WI, USA). Brieﬂy, SCs on 96-well plates were treated
with EPS for 24 h. After the treatment with EPS, the medium
containing detached cells was removed. Cells remaining on the 96-
well plates were washed with DMEM (FBS-free) and incubated
with fresh DMEM (100 μl) and MTS assay solution (10 ml) at 37 ˚C
for 60 min. The produced MTS formazan was measured at 490 nm
with a Bio-Rad Model 680 microplate reader (Hercules, CA, USA).
Flow cytometric detection of activated caspase-3
After treating SCs with EPS, the cells were ﬁxed with 4%
p-formaldehyde. Activated caspase-3 was detected by reacting with
an antibody speciﬁc for the cleaved form of caspase-3, anti-mouse
caspase-3 phycoerythrin (PE)-conjugated monoclonal antibody (sc-
7272 PE; Santa Cruz Biotechnology, Inc., CA, USA). Following
incubation with the antibody, the cells were washed with DPBS,
collected with a cell scraper, resuspended in DPBS, and analyzed
with a ﬂow cytometer (Beckman Colter, Fullerton CA, USA). Fluor-
escence was detected with ﬂuorescence channel 2 (FL2).
Measurement of γ-GCS and Nrf2 mRNA levels
Quantitative RT-PCR analysis was used to measure γ-GCS mRNA
and Nrf2 mRNA levels. Total RNA from treated cells was extracted
with RNAspin Mini (GE Healthcare, Buckinghamshire, UK) according
to the manufacturer's protocol. mRNAs were reverse-transcribed into
cDNA with a High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, USA). Quantitative RT-PCR was per-
formed with a 7500 Fast Real-Time PCR System (Applied Bio-
systems). Primers for rat γ-GCS (Rn00689046_g1) and rat Nrf2
(Rn00477784_m1) were purchased from Applied Biosystems. mRNA
levels were acquired from the value of the threshold cycle (Ct) of γ-
GCS or Nrf2, normalized to that of GAPDH. Relative mRNA levels
were compared and expressed as percentage of control levels.
Determination of nuclear Nrf2 translocation
Nuclear extracts of SCs were prepared using the Active Motif
Nuclear Extract Kit (Tokyo, Japan) according to the manufacturer's
protocol. The amount of active Nrf2 in the nuclear extracts was
determined by subjecting samples of 20 μg protein to assay with a
TransAM Nrf2 DNA Binding ELISA Kit (Active Motif). The assay was
performed according to the manufacturer's protocol.
Knockdown of Nrf2 with small interfering RNA (siRNA)
Oligonucleotides directed against rat Nrf2 and control siRNA
(Ambion, Austin, TX, USA) were transfected into SCs using Lipo-
fectamine RNAiMAX (Invitrogen, Eugene, OR, USA), according to
the manufacturer's protocol. Brieﬂy, both Nrf2 siRNA and control
siRNA were diluted with Opti-MEM medium and then, diluted
Lipofectamine RNAiMax was added. The transfection mixture was
incubated at room temperature for 20 min. When SCs reached 30–
50% conﬂuence, the culture medium was replaced with DMEM
(without FBS) and the transfection mixture was added to each
well. The ﬁnal concentration of siRNA was 50 nM. After SCs
transfected with Nrf2 siRNA and control siRNA were treated with
EPS, the effect of Nrf2 knockdown on intracellular GSH levels was
assessed.
Other procedures
Intracellular GSH levels were measured by spectrophotometric
methods, as described previously [15]. Aldose reductase activity
was measured according to the method described by Kawasaki
et al. [16] with DL-glyceraldehyde as the substrate. Protein con-
centrations were determined using the Bradford method with
bovine serum albumin as the standard.
Statistical analysis
All experiments were performed independently at least three
times. Data were combined and expressed as means7S.D. Statis-
tical signiﬁcance between two groups was evaluated using the
Student's t-test after analysis of variance or the Scheffe test after
the Kruskal–Wallis test. A P value of o0.05 was considered to be
signiﬁcant.
Results
Effect of EPS on viability of SCs
SCs were treated with EPS at the indicated concentrations for
24 h. As shown in Fig. 2A, aldose reductase activity was decreased
by 30–50% after treatment with 10–100 mM EPS. In this case,
however, dose-dependent differences were not observed. Fig. 2B
shows cell viability estimated by the MTS assay. EPS at 10 and
50 mM had no effect on cell viability. A signiﬁcant reduction in cell
viability could be observed at EPS concentrations of 100 and
200 mM. At those EPS concentrations, loss of viability was 4% and
18%, respectively, compared to control. Caspase-3 activation is
involved in the pathways for apoptosis. Fig. 2C shows the results of
ﬂow cytometric analyses with phycoerythrin-conjugated anti-
caspase-3 antibody. The ﬂuorescence intensities of SCs treated
with 100 and 200 mM EPS were shifted to the right side of the
SCH3
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Fig. 1. Chemical structure of epalrestat.
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panel compared to control. The increases in ﬂuorescence intensity
were approximately 1.7- and 2.6-fold (Fig. 2D). These results
suggest that increasing EPS concentration induces apoptosis
in SCs.
Effect of EPS on GSH in SCs
Next, we examined the effect of EPS on intracellular GSH levels.
As shown in Fig. 3A, treatment of SCs with EPS at 10 and 50 mM
caused a dramatic increase in intracellular GSH levels: the increases
were approximately 3.2- and 5.6-fold, respectively, compared to
control. A further increase in GSH levels could be observed at the
EPS concentration of 100 mM (data not shown). However, this EPS
concentration caused a loss of cell viability (Fig. 2), which was
probably concomitant with cell membrane damage. On the other
hand, sorbinil, another aldose reductase inhibitor [17], failed to
increase GSH levels (Fig. 3B). Fig. 3C demonstrates that EPS
increased the mRNA levels of γ-GCS, the enzyme catalyzing the
ﬁrst and rate-limiting step in de novo GSH synthesis. The γ-GCS
mRNA levels were increased by 1.2- and 2.6-fold by 10 and 50 mM
EPS, respectively. These results indicate that EPS increases intracel-
lular GSH levels in SCs through transcription regulation.
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Fig. 2. Effect of EPS on aldose reductase activity and viability of SCs. SCs were treated with EPS at the indicated concentrations for 24 h. (A) Aldose reductase activity. Values
are means7SD of three experiments. (B) Cell viability estimated by MTS assay. Values are means7SD of six experiments. (C) Caspase-3 activity measured by ﬂow cytometry
using phycoerythrin-conjugated anti-caspase-3 antibody. Each panel shows the typical ﬂuorescence intensity from three independent experiments. (D) Fluorometric analysis
of data shown in C. Values are means7SD of three experiments. *Signiﬁcant difference from the value of control (Po0.05).
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Effect of EPS on Nrf2 in SCs
Then, we further studied how EPS increased the levels of γ-
GCS. Recent studies have reported that Nrf2 plays a pivotal role in
inducing the expression of genes encoding detoxifying/defensive
proteins, including γ-GCS, by binding to the antioxidant response
element (ARE) [11–13]. The effect of EPS on Nrf2 activation/nuclear
translocation in SCs was tested by binding EPS to an ARE-speciﬁc
double-stranded oligonucleotide. Fig. 4A demonstrates that EPS
caused an increase in the nuclear level of active Nrf2. The nuclear
levels of active Nrf2 were increased by 1.8- and 3.8-fold by
treatment with 10 and 50 mM EPS, respectively, and the increase
was similar to that of γ-GCS mRNA levels. In contrast, EPS failed to
increase Nrf2 mRNA levels (Fig. 4B).
We examined whether Nrf2 levels could alter the increases in
γ-GCS mRNA and GSH levels of cells treated with 10 and 50 mM
EPS, by means of Nrf2 knockdown in SCs. SCs were transfected
with control siRNA (siControl) or Nrf2 siRNA (siNrf2). Nrf2 mRNA
expression levels in cells transfected with Nrf2 siRNA were
reduced by 61% relative to those in control siRNA transfected cells
(data not shown). As shown in Fig. 4C and D, the increase in γ-GCS
mRNA and GSH levels after EPS treatment was inhibited by the
knockdown of Nrf2 expression using siRNA. These results suggest
that EPS induces GSH biosynthesis by up-regulating γ-GCS via the
activation of Nrf2 in SCs.
Effect of EPS on oxidative stress in SCs
Finally, we examined whether EPS could protect SCs from
oxidative stress. SCs were pretreated with EPS (50 mM) for 16 h
and then exposed to oxidizing agents. After exposure for 24 h, cell
viability was assessed by the MTS assay. The exposures to H2O2
and tert-butylhydroperoxide resulted in approximately 70% and
80% cytotoxicity, respectively (Fig. 5A and B). EPS signiﬁcantly
reduced the cytotoxicity induced by the exposure to the peroxides.
In addition, EPS reduced the cytotoxicity induced by 2,2'-azobis (2-
amidinopropane) dihydrochloride, a free-radical-generating azo
compound [18] (Fig. 5C). Furthermore, EPS reduced the cytotoxi-
city induced by menadione, a redox-cycling quinone known to
cause oxidative stress [19], in SCs (Fig. 5D). N-Acetyl-L-cysteine (a
precursor of GSH) or GSH monoethyl ester (a cell-permeable
derivative of GSH) also reduced the cytotoxicity induced by these
oxidants, while DL- buthionine-(S,R)-sulfoximine (an inhibitor of
γ-GCS) completely abolished the protective effect of EPS against
H2O2-induced cytotoxicity (data not shown).
Discussion
EPS (Ono Pharmaceuticals, Osaka, Japan), approved in Japan in
1992, is the only aldose reductase inhibitor currently available for
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Fig. 3. Effect of EPS on GSH and γ-GCS mRNA levels in SCs. (A) Intracellular GSH levels. SCs were treated with 10 or 50 mM EPS for 24 h. (B) GSH levels were measured after
treatment with 50 mM EPS or 50 mM sorbinil for 24 h. (C) γ-GCS mRNA levels. SCs were treated with 10 or 50 mM EPS for 4 h. Values are means7SD of three experiments.
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the treatment of diabetic neuropathy. EPS is easily absorbed by
neural tissue and inhibits aldose reductase with minimum adverse
effects [20]. A recent study showed that treatment with EPS at an
early stage delayed the progression of diabetic neuropathy
and prevented the onset/progression of retinopathy and nephro-
pathy [21]. The usual dosage of EPS for oral use is 50 mg three
times a day. The plasma EPS concentration of 3.9 mg/ml (12 mM)
was observed 1 h after a single oral dose of 50 mg [22]. In this
study, we demonstrated for the ﬁrst time that EPS at near-plasma
concentration exerted biological effects other than aldose reduc-
tase inhibition on cells.
GSH, the most abundant antioxidant, plays an essential role in
maintaining the cellular redox state [9]. The present study demon-
strated that EPS increased intracellular GSH and γ-GCS mRNA
levels in SCs (Fig. 3A and C). Increasing the concentration of EPS
resulted in an increase in GSH level. In contrast, no signiﬁcant
dose-dependent effect of EPS on aldose reductase activity was
observed (Fig. 2A), implying that the inhibition of aldose reductase
does not contribute to the ability of EPS to increase GSH levels.
Indeed, sorbinil, another aldose reductase inhibitor, [17] failed to
increase GSH levels (Fig. 3B). On the other hand, the knockdown of
Nrf2, which regulates GSH levels by controlling the expression of
γ-GCS gene [11–13], suppressed the increase in GSH and γ-GCS
mRNA levels after EPS treatment (Fig. 4C and D). Moreover, the
activation/nuclear translocation of Nrf2 was observed after treat-
ment with EPS, although EPS did not affect the mRNA level of Nrf2
(Fig. 4A and B). Taken together, these results provide strong
evidence that EPS stimulates GSH biosynthesis by up-regulating
γ-GCS via Nrf2. Under unstimulated conditions, Nrf2 is seques-
tered in the cytoplasm where it associates with Keap1 [11–13].
Nrf2 can be translocated into the nucleus to bind to ARE when the
Keap1–Nrf2 complex is dissociated by some form of cellular
stimuli. Therefore, the EPS-stimulated Nrf2 activation may be
mediated by the dissociation of the Keap1–Nrf2 complex, rather
than by Nrf2 transcription. Meanwhile, treatment with siNrf2 did
not completely decrease intracellular GSH to baseline levels
despite complete inhibition of γ-GCS mRNA (Fig. 4C and D).
A very recent study has demonstrated that activation of Nrf2
results in increased release of GSH [23]. It is possible that
treatment with siNrf2 decreases GSH released from cells, thereby
leading to the intracellular GSH accumulation.
Oxidative stress is associated with the development and
progression of numerous pathological conditions, such as athero-
sclerosis [7,8], diabetes [6], and neurodegeneration [4,5]. It is
important to ﬁnd ways to increase the intracellular GSH level in
order to prevent and/or minimize ROS-induced cellular damage.
We assumed that EPS might play a role in protecting against
oxidative stress. To determine whether EPS protects SCs from
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oxidative stress, we performed experiments by using H2O2,
tert-butylhydroperoxide, 2,2'-azobis (2-amidinopropane) dihy-
drochloride or menadione [18,19] as the source of oxidative stress.
Pretreatment with EPS at 50 mM clearly protected SCs from toxicity
induced by these oxidizing agents (Fig. 5), indicating that EPS acts
to suppress oxidative damage in cells and tissues. It was shown
that EPS improved impaired superoxide generation in
streptozotocin-induced diabetic rats [24]. In addition, EPS reduced
plasma thiobarbituric acid reactive substances [25] or lipid per-
oxide level [26], an index of oxidative stress, in type 2 diabetic
patients. These ﬁndings suggest that EPS has new beneﬁcial
properties that may prevent the development and progression of
disorders caused by oxidative stress.
Hypoxia, hyperglycemia, and oxidative stress contribute
directly and indirectly to SC dysfunction [27]. SCs respond to
oxidative stress via the activation of Nrf2 [28]. Nrf2 is a key
transcriptional activator of the antioxidant response pathway. Our
present data showed that EPS protected SCs from oxidative stress,
presumably by increasing GSH levels through the up-regulation of
γ-GCS via the activation of Nrf2. However, Nrf2 controls not only
γ-GCS gene but also the genes of many cytoprotective enzymes,
such as superoxide dismutase, catalase, glutathione peroxidase,
and heme oxygenase-1 [28–30]. Therefore, we speculate that the
EPS-induced resistance to oxidative stress in SCs is associated with
the increased expression of some other cytoprotective enzymes,
including γ-GCS. EPS contains an α,β-unsaturated ketone moiety
within its structure. α,β-unsaturated ketones can act as inducers
of ARE genes through the oxidation of sulfhydryl groups in Keap1
leading to dissociation and nuclear translocation of Nrf2 [31].
EPS-stimulated Nrf2 activation is most likely to be achieved by
alterations in the structure of Keap1. On the other hand, the main
metabolite of EPS is known to be the sulfate conjugate of a mono-
OH or a di-OH compound [22]. However, at present, the contribu-
tion of EPS metabolites to the increase in GSH levels is unclear.
Further extensive investigations will be required to clarify the
protective mechanism of EPS against oxidative stress.
In the present study, a signiﬁcant reduction in cell viability was
observed at EPS concentrations of 100 and 200 mM, concomitantly
causing caspase-3 activation (Fig. 2). This result indicates that
increasing EPS concentration may induce the apoptosis of SCs. One
report described that exposing human colon adenocarcinoma cells
to 50 or 100 mM EPS enhanced lipid peroxide levels and cell
survival, indicating that the inhibition of aldose reductase leads
to carbonyl-induced cell death [32]. A very recent study has shown
that ﬁdarestat, a potent inhibitor of aldose reductase [33], potenti-
ates the apoptosis of human colon cancer cells through the down-
regulation of cell survival proteins and the up-regulation of death
receptors [34]. Consequently, one possibility is that the strong
inhibition of aldose reductase under high-EPS conditions may
perturb the function and survival of cells.
Drug re-proﬁling has emerged as a new strategy for drug
discovery and development and a way to identify new treatments
for diseases [35]. In this strategy, the pharmacological action of
existing medicines whose safety and pharmacokinetics have
already been conﬁrmed clinically and whose use has been
approved is examined comprehensively at the molecular level
and the results are adopted for the development of new medi-
cines. The results can also be applied to the development of
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existing drugs for use as medicines for the treatment of other
diseases. The present study may lead to breakthroughs in drug
discovery and development. We showed here that EPS induces
GSH synthesis and apoptosis, suggesting both beneﬁcial and
damaging effects of EPS. The therapeutic EPS dose might be a
new strategy useful for improving oxidative stress-related diverse
diseases including neurodegenerative diseases and atherosclerosis
as well as diabetes.
In summary, we demonstrated for the ﬁrst time that EPS at
near-plasma concentration increases intracellular GSH levels
through transcription regulation. EPS can activate Nrf2, which
induces GSH biosynthesis, resulting in enhanced resistance to
oxidative stress. As oxidative stress and low GSH levels are the
key contributors to aging and chronic diseases, EPS may be
effective in preventing and/or attenuating the progress of those
processes.
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